Recent studies raised concern that incretin treatment might be accompanied by a proliferative effect on the exocrine pancreas, leading to histological changes, pancreatitis and an increased risk of pancreatic cancer in the long run [22-25,42], although these observations were not confirmed by other reports [9,17,51-54]. The gene discussed is GCG; the disease is familial pancreatic carcinoma.